[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 22, 1974

Carbenoxolone Sodium in the Treatment of Peptic Ulcer: A Review

Author Affiliations

Dr. Lewis is Senior Scientist, AMA Department of Drugs.

JAMA. 1974;229(4):460-462. doi:10.1001/jama.1974.03230420072036

THE dates on which several new therapeutic agents were introduced in the United States and Great Britain have recently been compared by Wardell.1 He also conducted a survey on the usage of these new drugs by British physicians, and the awareness of them by American physicians.2

Among the drugs available in Great Britain but not in this country, carbenoxolone sodium is notable for two reasons: (1) the "lead" time that it has been available in Great Britain is among the longest of the drugs surveyed (ten years), and (2) it is recognized as "the only drug therapy that has been shown unequivocally to promote the healing of gastric ulcers."1

Several reviews of carbenoxolone have appeared in the foreign literature3-6 but, with the exception of one report on the proceedings of a symposium,7 only a brief summary of the drug's actions by Wolf8 has been published